Companies · Pharmaceuticals
HOUSTON · Pharmaceuticals
Diligence memoA one-page analyst read on 7 Hills Pharma Inc. — recommendation, valuation, rhythm, risks.→7 Hills Pharma Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
7 Hills Pharma Inc. is one of 1610 Pharmaceuticals companies tracked from HOUSTON. By capital raised it ranks in the long tail (ahead of 20% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 20% of sector peers (real $). Modeled value above 9% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #9 of 38.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Eleison Pharmaceuticals Inc | Pre-Seed | $980K | $15.9M | 6.25× |
| Telomir Pharmaceuticals, Inc. | Pre-Seed | $1.0M | $9.7M | 3.81× |
| Drusolv Therapeutics, Inc. | Pre-Seed | $500K | $8.5M | 3.33× |
| TF Tech Ventures, Inc. | Pre-Seed | $625K | $8.3M | 3.25× |
| Thyron Pharmaceuticals, Inc. | Pre-Seed | $500K | $8.2M | 3.23× |
| Gelesis Holdings, Inc. | Pre-Seed | $576K | $7.9M | 3.10× |
| MEDPhlow, LLC | Pre-Seed | $1.0M | $6.5M | 2.57× |
| Centaur Bio Inc. | Pre-Seed | $1.5M | $5.5M | 2.15× |
| 7 Hills Pharma Inc. this company | Pre-Seed | $1.0M | $4.9M | 1.94× |
| Artin Bioscience Inc. | Pre-Seed | $483K | $4.8M | 1.88× |
| Precision Genetics, Inc. | Pre-Seed | $1.0M | $4.8M | 1.87× |
| Zena Therapeutics Inc. | Pre-Seed | $500K | $3.8M | 1.50× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $1.0M | 2024-05-09 | $5.6M | $4.9M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Joseph Bailes | — | 1 other | 2024-05 |
| Upendra Marathi | — | 1 other | 2024-05 |
| Kala Marathi | — | — | 2024-05 |
| Robert A. Bent | — | — | 2024-05 |
| Stephen A. Bent | — | — | 2024-05 |
7 Hills Pharma Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| ABLi Therapeutics, Inc. | Pharmaceuticals | Pre-Seed | $1.0M | $2.2M | same sector · same stage |
| Adora Animal Health Corp | Pharmaceuticals | Pre-Seed | $1.0M | $2.5M | same sector · same stage |
| Akanocure Pharmaceuticals, LLC | Pharmaceuticals | Pre-Seed | $1.0M | $1.4M | same sector · same stage |
| Applied Bioresearch, Inc. | Pharmaceuticals | Pre-Seed | $1.0M | $11.8M | same sector · same stage |
| Essentia Pharma Mountain West, LLC | Pharmaceuticals | Pre-Seed | $1.0M | $1.4M | same sector · same stage |
| Essentia Pharma South, LLC | Pharmaceuticals | Pre-Seed | $1.0M | $1.4M | same sector · same stage |
| MEDPhlow, LLC | Pharmaceuticals | Pre-Seed | $1.0M | $6.5M | same sector · same stage |
| Monterey Pharmaceuticals, LLC | Pharmaceuticals | Pre-Seed | $1.0M | $1.4M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Forty Seven, Inc. | Pharmaceuticals | Series C | $2.6B | 83% |
| Nob Hill Therapeutics, Inc. | Pharma | Seed | $8.0M | 78% |
| Balanced Pharma Inc | Pharmaceuticals | Seed | $641K | 77% |
| RedHill Biopharma Ltd. | Pharmaceuticals | Series C | $101.6M | 77% |
| PharmID, Inc. | Pharmaceuticals | Series A | $154.9M | 76% |
| Elevation Oncology, Inc. | Pharma | Series C | $2.0B | 75% |
| Land Medicine Inc. | Pharmaceuticals | Series B | $97.8M | 75% |
| BlossomHill Therapeutics, Inc. | Pharmaceuticals | Series C | $452.2M | 75% |
See where 7 Hills Pharma Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at 7 Hills Pharma Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.